← Oncology Approval Tracker

FDA DECISION ·

Piqray + fulvestrant

alpelisib with fulvestrant · Novartis

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Expanded to premenopausal and perimenopausal women with HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after progression on endocrine therapy, as part of the adult indication with fulvestrant and FDA-approved mutation testing.

LAMPGEN ANALYSIS

Why it matters

The supplement broadened the labeled population and updated guidance for managing hyperglycemia.

What research teams should watch

Document menopausal status and any ovarian suppression plan, and set up baseline glucose and early follow-up.

PRIMARY RECORDS

Sources